Merck (MRK) Gross Margin (2009 - 2026)
Merck (MRK) reported Gross Margin of 74.24% for Q1 2026, down 374.0% year-over-year from 27.1% in Q1 2025, and up 12.23% quarter-over-quarter from 66.15% in Q4 2025.
Merck (MRK) Gross Margin (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Gross Margin data on file, last reported at 74.24% in Q1 2026.
- Gross Margin for Q1 2026 came in at 74.24%, down 374.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 73.91% (down 251.0% YoY), and the FY2025 annual result was 74.8%, down 152.0% from the prior year.
- Gross Margin grew to 74.24% in Q1 2026 per MRK's latest filing, from 66.15% in the prior quarter.
- Over five years, Gross Margin peaked at 77.98% in Q1 2025 and troughed at 66.15% in Q4 2025.
- A 5-year average of 73.79% and a median of 73.7% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2025: Gross Margin surged 673 bps in 2023, then sank 935 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 71.94% in 2022, then increased by 2 bps to 73.26% in 2023, then grew by 3 bps to 75.5% in 2024, then retreated by 12 bps to 66.15% in 2025, then climbed by 12 bps to 74.24% in 2026.
- Business Quant data shows MRK's Gross Margin at 74.24% in Q1 2026, 66.15% in Q4 2025, and 77.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 70.22% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.24% |
| Dec 31, 2025 | 66.15% |
| Sep 30, 2025 | 77.69% |
| Jun 30, 2025 | 77.50% |
| Mar 31, 2025 | 77.98% |
| Dec 31, 2024 | 75.50% |
| Sep 30, 2024 | 75.51% |
| Jun 30, 2024 | 76.76% |
| Mar 31, 2024 | 77.56% |
| Dec 31, 2023 | 73.26% |
| Sep 30, 2023 | 73.29% |
| Jun 30, 2023 | 73.24% |
| Mar 31, 2023 | 72.90% |
| Dec 31, 2022 | 71.94% |
| Sep 30, 2022 | 73.70% |
| Jun 30, 2022 | 71.11% |
| Mar 31, 2022 | 66.17% |
| Dec 31, 2021 | 71.35% |
| Sep 30, 2021 | 73.77% |
| Jun 30, 2021 | 72.78% |